These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38970270)

  • 21. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial.
    Razmpoosh E; Javadi A; Ejtahed HS; Mirmiran P; Javadi M; Yousefinejad A
    Diabetes Metab Syndr; 2019; 13(1):175-182. PubMed ID: 30641692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of traditional Chinese medicine on gut microbiota in adults with type 2 diabetes: A systematic review and meta-analysis.
    Zheng Y; Ding Q; Wei Y; Gou X; Tian J; Li M; Tong X
    Phytomedicine; 2021 Jul; 88():153455. PubMed ID: 33478831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serine racemase rs391300 G/A polymorphism influences the therapeutic efficacy of metformin in Chinese patients with diabetes mellitus type 2.
    Dong M; Gong ZC; Dai XP; Lei GH; Lu HB; Fan L; Qu J; Zhou HH; Liu ZQ
    Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):824-9. PubMed ID: 21933224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL; Williams-Herman D; Xu L; Golm GT; Wang H; Dong Q; Johnson JR; O'Neill EA; Kaufman KD; Engel SS; Goldstein BJ
    Curr Med Res Opin; 2015 Jun; 31(6):1071-7. PubMed ID: 25850968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of acarbose and metformin on the inflammatory state in newly diagnosed type 2 diabetes patients: a one-year randomized clinical study.
    Mo D; Liu S; Ma H; Tian H; Yu H; Zhang X; Tong N; Liao J; Ren Y
    Drug Des Devel Ther; 2019; 13():2769-2776. PubMed ID: 31496653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined effects of
    Shin NR; Gu N; Choi HS; Kim H
    Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E52-E61. PubMed ID: 31770016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study.
    Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M
    Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus.
    Ochoa-Morales PD; González-Ortiz M; Martínez-Abundis E; Pérez-Rubio KG; Patiño-Laguna ADJ
    Int J Vitam Nutr Res; 2023 Dec; 93(6):498-506. PubMed ID: 35965421
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial.
    Kassaian N; Feizi A; Aminorroaya A; Jafari P; Ebrahimi MT; Amini M
    Acta Diabetol; 2018 Oct; 55(10):1019-1028. PubMed ID: 29931423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
    Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
    Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and chronic periodontitis.
    Sun WL; Chen LL; Zhang SZ; Wu YM; Ren YZ; Qin GM
    Intern Med; 2011; 50(15):1569-74. PubMed ID: 21804283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.